Osteomon Profile

The test measures the levels of Beta 2 Crosslaps (B-CTx) and P1NP (Total procollagen type 1 amino terminal propeptide), in the blood.

• To assess the risk of fractures or bone disorders
• To assess the bone status in those receiving treatment [eg osteoporotic patients]
• Used to monitor status of osteoporosis.

People with the following symptoms:

• Frequent bone pain
• Frequent fractures
• History of osteoporosis, Paget’s disease or any bone disorder
• Patients receiving drug therapy for bone disorders: To monitor the treatment effectiveness.

This test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.

No special precautions required.

Beta 2 Crosslaps (B-CTx)

Elevated levels are seen in patients with increased bone resorption. Increased levels of B-CTX occur in osteoporosis, Paget’s disease, primary hyperparathyroidism, renal insufficiency and bone metastases.

A drop in CTX concentration of 35 percent to 55 percent from baseline levels after three to six months indicates effective antiresorptive therapy. The absence of a decline in CTX concentration may indicate ineffective antiresorptive therapy or lack of compliance by the patient.

P1NP:

Significantly elevated levels may be associated with presence of metastatic bone disease and renal insufficiency

• Beta 2 Crosslaps test
• P1NP test
• Osteoporosis test

• It is a specific indicator of type 1 collagen deposition and is defined as a true bone formation marker.
•  It is particularly useful for monitoring bone formation therapies (in post-menopausal osteoporosis, Paget’s disease etc) and antiresorptive therapies.

• It is a biochemical marker of bone resorption.
• CTx is useful to assess bone resorption in patients with metabolic bone disease. It is used as an aid in monitoring antiresorptive therapies.